Squamous cell carcinoma - Ploščatocelični Karcinom
☆ V rezultatih raziskave Stiftung Warentest iz Nemčije leta 2022 je bilo zadovoljstvo potrošnikov z ModelDermom le nekoliko nižje kot s plačanimi telemedicinskimi svetovanji.
Squamous cell carcinoma well differentiated ― Opažena je sosednja aktinična keratoza.
References
Squamous cell carcinoma (SCC) je drugi najpogostejši kožni rak v Združenih državah, takoj za basal cell carcinoma. Običajno se začne s predrakavimi lezijami, imenovanimi actinic keratosis , in se lahko razširi na druge dele telesa. Glavni vzrok je izpostavljenost ultravijoličnemu (UV) sevanju sonca, ki se sčasoma kopiči. Zdravljenje običajno vključuje kirurško odstranitev, zlasti pri SCC na glavi in vratu. Radioterapija je možnost za starejše bolnike ali tiste, ki ne morejo na operacijo. Imunosupresija poveča tveganje za SCC. Čeprav je redek, se SCC lahko razširi, zlasti pri bolnikih z oslabljenim imunskim sistemom. Za bolnike s SCC so pomembni redni pregledi in zaščita pred soncem.
Squamous cell carcinoma of the skin or cutaneous squamous cell carcinoma is the second most common form of skin cancer in the United States, behind basal cell carcinoma. Squamous cell carcinoma has precursor lesions called actinic keratosis, exhibits tumor progression and has the potential to metastasize in the body. Ultraviolet (UV) solar radiation is the primary risk factor in the development of cutaneous squamous cell carcinoma and the cumulative exposure received over a lifetime plays a major part in the development of this cancer. Surgical excision is the primary treatment modality for cutaneous squamous cell carcinoma, with Mohs micrographic surgery being the preferred excisional technique for squamous cell carcinoma of the head and neck, and in other areas of high risk or squamous cell carcinoma with high-risk characteristics. Radiation therapy is reserved for squamous cell carcinoma in older patients or those who will not tolerate surgery, or when it has not been possible to obtain clear margins surgically. Adjuvant radiotherapy is commonly after surgical treatment in very high tumors. Immunosuppression significantly increases the risk of squamous cell carcinoma over the course of an individual’s life. Metastasis is uncommon for squamous cell carcinomas arising in areas of chronic sun exposure, but it can take place, and the risk is increased in immunosuppressed patients. Patients with cutaneous squamous cell carcinoma should be examined regularly and remember to use measures to protect from UV damage.
Squamous cell carcinoma of the skin or cutaneous squamous cell carcinoma is the second most common form of skin cancer in the United States, behind basal cell carcinoma. Squamous cell carcinoma has precursor lesions called actinic keratosis, exhibits tumor progression and has the potential to metastasize in the body. Ultraviolet (UV) solar radiation is the primary risk factor in the development of cutaneous squamous cell carcinoma and the cumulative exposure received over a lifetime plays a major part in the development of this cancer. Surgical excision is the primary treatment modality for cutaneous squamous cell carcinoma, with Mohs micrographic surgery being the preferred excisional technique for squamous cell carcinoma of the head and neck, and in other areas of high risk or squamous cell carcinoma with high-risk characteristics. Radiation therapy is reserved for squamous cell carcinoma in older patients or those who will not tolerate surgery, or when it has not been possible to obtain clear margins surgically. Adjuvant radiotherapy is commonly after surgical treatment in very high tumors. Immunosuppression significantly increases the risk of squamous cell carcinoma over the course of an individual’s life. Metastasis is uncommon for squamous cell carcinomas arising in areas of chronic sun exposure, but it can take place, and the risk is increased in immunosuppressed patients. Patients with cutaneous squamous cell carcinoma should be examined regularly and remember to use measures to protect from UV damage.
Cutaneous squamous cell carcinoma (CSCC) je drugi najpogostejši rak pri ljudeh in njegovo število narašča. Čeprav CSCC običajno kaže benigno klinično vedenje, se lahko razširi lokalno in na druge dele telesa. Znanstveniki so identificirali posebne poti, vključene v razvoj CSCC, kar vodi do novih zdravljenj. Veliko število mutacij in povečano tveganje pri imunosupresiranih bolnikih sta spodbudila razvoj imunoterapije. Ta pregled obravnava genetske korenine CSCC in najnovejše načine zdravljenja, ki ciljajo na specifične molekule in imunski sistem.
Cutaneous squamous cell carcinoma (CSCC) is the second most frequent cancer in humans and its incidence continues to rise. Although CSCC usually display a benign clinical behavior, it can be both locally invasive and metastatic. The signaling pathways involved in CSCC development have given rise to targetable molecules in recent decades. In addition, the high mutational burden and increased risk of CSCC in patients under immunosuppression were part of the rationale for developing the immunotherapy for CSCC that has changed the therapeutic landscape. This review focuses on the molecular basis of CSCC and the current biology-based approaches of targeted therapies and immune checkpoint inhibitors
Cutaneous squamous cell carcinoma (CSCC) is the second most frequent cancer in humans and its incidence continues to rise. Although CSCC usually display a benign clinical behavior, it can be both locally invasive and metastatic. The signaling pathways involved in CSCC development have given rise to targetable molecules in recent decades. In addition, the high mutational burden and increased risk of CSCC in patients under immunosuppression were part of the rationale for developing the immunotherapy for CSCC that has changed the therapeutic landscape. This review focuses on the molecular basis of CSCC and the current biology-based approaches of targeted therapies and immune checkpoint inhibitors
○ Diagnoza in zdravljenje
#Dermoscopy
#Skin biopsy